Stock comparison
IDEXX Laboratories
Masimo
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
MASI
Masimo
Market cap
$9.35B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MASI | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 39D | IDXX |
| Benjamin Graham | 72B | 66B | IDXX |
| Philip Fisher | 67B | 40D | IDXX |
| Peter Lynch | 63C | 26F | IDXX |
| Joel Greenblatt | 75B | 53C | IDXX |
| Charlie Munger | 79B | 42D | IDXX |
| Terry Smith | 76B | 33F | IDXX |
Side-by-side metrics
| Metric | IDXX | MASI |
|---|---|---|
| Market cap | $42.11B | $9.35B |
| P/E (TTM) | 39.0x | 122.1x |
| EV/EBIT | 31.6x | 31.0x |
| ROIC (TTM) | 40.66% | 18.28% |
| Gross margin | 62.05% | 61.73% |
| Net margin | 24.63% | 4.9% |
| Revenue CAGR 5y | 7.56% | 5.36% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.6x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs 4.9%+80%
- Market cap$42.11Bvs $9.35B+78%
- P/E (TTM)39.0xvs 122.1x+68%
- ROIC (TTM)40.66%vs 18.28%+55%
MASI leads on
- Debt / Equity0.6xvs 0.7x+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.